Patents by Inventor Marco Berrera

Marco Berrera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20220042022
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 10, 2022
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
    Publication number: 20210147850
    Abstract: The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 20, 2021
    Inventors: Marco BERRERA, Josephine FELBER, Jean-Christophe HOFLACK, Susanne KAMMLER, Tony KAM-THONG, Brian LEONARD, Lykke PEDERSEN, Philipp TROPBERGER, Miriam TRIYATNI, Daniel Jeremy TURLEY, Angelina WALLIER, Jitao David ZHANG
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20200157546
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 21, 2020
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20190055564
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: May 29, 2018
    Publication date: February 21, 2019
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann